High mortality in fully vaccinated hematologic patients treated with anti-CD20 antibodies during the "Omicron wave" of COVID-19 pandemic.
作者信息
Cattaneo Chiara, Masina Lorenzo, Pagani Chiara, Cancelli Valeria, Daffini Rosa, Tucci Alessandra, Rossi Giuseppe
机构信息
Haematology, ASST Spedali Civili, Brescia, Italy.
出版信息
Hematol Oncol. 2023 Feb;41(1):205-207. doi: 10.1002/hon.3064. Epub 2022 Aug 19.
Abstract
摘要
相似文献
1
High mortality in fully vaccinated hematologic patients treated with anti-CD20 antibodies during the "Omicron wave" of COVID-19 pandemic.在新冠疫情“奥密克戎浪潮”期间，接受抗CD20抗体治疗的血液学患者中，完全接种疫苗者死亡率较高。
Hematol Oncol. 2023 Feb;41(1):205-207. doi: 10.1002/hon.3064. Epub 2022 Aug 19.
2
A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.奥密克戎变异株早期完全接种疫苗的多发性硬化症接受抗 CD20 治疗患者 COVID-19 后血清转换的回顾性评估。
Mult Scler Relat Disord. 2023 Mar;71:104574. doi: 10.1016/j.msard.2023.104574. Epub 2023 Feb 15.
3
The Evolving Impact of Myocardial Injury in Patients With COVID-19 Amid the Omicron Wave of the Pandemic.奥密克戎疫情期间 COVID-19 患者心肌损伤的不断演变的影响。
Am J Cardiol. 2023 Mar 1;190:54-60. doi: 10.1016/j.amjcard.2022.11.041. Epub 2022 Dec 21.
4
Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan.巴基斯坦第五波疫情期间出现的 SARS-CoV-2 奥密克戎和德尔塔变异突破性病例。
Front Public Health. 2022 Sep 29;10:987452. doi: 10.3389/fpubh.2022.987452. eCollection 2022.
5
The management of hematologic malignancies during the COVID-19 pandemic.COVID-19 大流行期间血液系统恶性肿瘤的管理。
Expert Opin Pharmacother. 2021 Apr;22(5):565-582. doi: 10.1080/14656566.2020.1849143. Epub 2020 Dec 21.
6
The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai.奥密克戎变异株在上海流行期间疫苗接种对 COVID-19 患者的影响。
Front Public Health. 2022 Nov 9;10:1054313. doi: 10.3389/fpubh.2022.1054313. eCollection 2022.
7
Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.与未接种疫苗的患者相比，使用主要生物标志物比较感染 SARS-CoV-2 Delta 或 Omicron VOC 患者的疾病严重程度和同源疫苗接种效果。
J Med Virol. 2022 Dec;94(12):5867-5876. doi: 10.1002/jmv.28098. Epub 2022 Sep 9.
8
Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.接种疫苗的造血干细胞移植受者 COVID-19 结局良好：单中心经验。
Transpl Infect Dis. 2023 Jun;25(3):e14024. doi: 10.1111/tid.14024. Epub 2023 Feb 7.
9
Omicron BA.5 Subvariant Provokes the Fifth COVID-19 Wave in Mexico: Closer to the End of This Pandemic.奥密克戎BA.5亚变体在墨西哥引发第五波新冠疫情：这场大流行接近尾声。
Disaster Med Public Health Prep. 2023 Jan 11;17:e344. doi: 10.1017/dmp.2023.14.
10
No excess mortality among working-age Italians during the Omicron wave of Covid-19.在新冠病毒奥密克戎变异株流行期间，意大利工作年龄人群的超额死亡率并不高。
Med Lav. 2022 Jun 28;113(3):e2022030. doi: 10.23749/mdl.v113i3.13092.
引用本文的文献
1
Impact of Cancer Subtype and Cancer Therapy Exposures on SARS-CoV-2 Outcomes in the Omicron and Subvariant Era.癌症亚型和癌症治疗暴露对奥密克戎及其亚型流行时代严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染结局的影响
Cancer Med. 2025 Jul;14(14):e71082. doi: 10.1002/cam4.71082.
2
Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China.在奥密克戎变异株流行期间，灭活疫苗剂量和血清 IgG 水平与中国血液恶性肿瘤患者持续性 COVID-19 感染相关。
BMC Infect Dis. 2024 Oct 11;24(1):1141. doi: 10.1186/s12879-024-10063-2.
3
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy.血液系统疾病患者和细胞治疗接受者的奥密克戎SARS-CoV-2感染管理及结局
Front Oncol. 2024 Jun 19;14:1389345. doi: 10.3389/fonc.2024.1389345. eCollection 2024.
4
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.一项国际多中心研究比较了奥密克戎变异株在接受奥滨尤妥珠单抗与利妥昔单抗治疗的血液系统恶性肿瘤患者中的结局。
Cancer Med. 2024 Feb;13(3):e6997. doi: 10.1002/cam4.6997.
5
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.奥密克戎相关的 COVID-19 血液病患者防治措施及血液学治疗方案调整策略。
Front Cell Infect Microbiol. 2023 Oct 19;13:1207225. doi: 10.3389/fcimb.2023.1207225. eCollection 2023.
6
Timing of BNT162b2 vaccine prior to COVID-19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study.BNT162b2 疫苗在 COVID-19 感染前的接种时机对血液系统恶性肿瘤患者疾病严重程度的影响：一项队列研究的结果。
Cancer Med. 2023 Nov;12(21):20503-20510. doi: 10.1002/cam4.6397. Epub 2023 Oct 25.
7
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者在奥密克戎毒株流行期间对新冠病毒2的全身和黏膜适应性免疫
Haematologica. 2024 Feb 1;109(2):646-651. doi: 10.3324/haematol.2023.282894.
本文引用的文献
1
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间，加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局，期间 B.1.617.2（德尔塔）和 B.1.1.529（奥密克戎）变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
2
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.COVID-19 疫苗在血液系统恶性肿瘤患者中的免疫原性：系统评价和荟萃分析。
Blood Adv. 2022 Apr 12;6(7):2014-2034. doi: 10.1182/bloodadvances.2021006333.
3
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA.接种疫苗的血液系统恶性肿瘤成年患者中的 COVID-19：来自 EPICOVIDEHA 的初步结果。
Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.
4
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.BNT162b2mRNA 新冠疫苗在全国大规模疫苗接种环境中对血液系统恶性肿瘤患者的有效性。
Blood. 2022 Mar 10;139(10):1439-1451. doi: 10.1182/blood.2021013768.
5
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).COVID-19 感染成年血液病患者：欧洲血液学协会调查（EPICOVIDEHA）。
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
6
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.COVID-19 血液病患者中特定抗体的产生和持续存在：利妥昔单抗的作用。
Blood Cancer J. 2021 Sep 14;11(9):151. doi: 10.1038/s41408-021-00546-9.
7
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.COVID-19 感染血液系统疾病患者的临床特征和死亡风险因素。
Cancer. 2020 Dec 1;126(23):5069-5076. doi: 10.1002/cncr.33160. Epub 2020 Sep 10.
8
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.意大利血液系统恶性肿瘤患者中与COVID-19严重程度相关的临床特征和危险因素：一项回顾性、多中心队列研究。
Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.
9
Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time.随着时间推移，血液学患者中新冠病毒病（COVID-19）的发病率降低，预后改善。
Leukemia. 2021 Feb;35(2):632-634. doi: 10.1038/s41375-020-01015-1. Epub 2020 Aug 7.
Zotero 插件